At Coretag, we are committed to developing our Tumor Necrosis Targeting Platform®, providing a novel first in class (FIC) diagnosis and treatment option for cancer patients. This therapy is expected to have limited side effects concerning Coretag’s novel ligands and known acceptable safety profile of the labeled radioisotopes, is affordable, and contributes to the fight against various aggressive forms of solid tumors. Our clinical strategy is to embark on “theranostics” modality with Step 1 serving as diagnosis of tumor necrosis (NC-Scan®), and Step 2 as treatment part (CyanCore Therapy®).
Download Coretag’s Company Introduction (PDF)
RLT Market
The radiopharmaceuticals market size is projected to reach $26.51 billion by 2031, up from $9.07 billion in 2023. This market is expected to grow at a compound annual growth rate (CAGR) of 14.4% during 2023–2031. Advances in radiopharmacy facilities, using cutting-edge diagnostic techniques, are likely to set new trends in the radiopharmaceuticals market. This growth is driven by factors such as the rising incidence of cancer and an aging population. (Source: Meditech Insiders, The Insight Partners). After Novartis began focusing on RLT with the acquisition of Advanced Accelerator Applications in 2017 and Endocyte in 2018, BMS and Eli Lilly followed suit in 2023 by acquiring RayzeBio and Point Biopharma, respectively. In May 2024, Novartis acquired Mariana Oncology, and AstraZeneca acquired Fusion Pharmaceuticals, further expanding the RLT market ambitions. With the growth of radiopharmaceuticals, the production and distribution of therapeutic isotopes like Lutetium-177 and Lead-212 is also improving, increasing the acceptance and availability of RLTs.
Coretag Strategy
Currently we are initiating our fundraising to fund the execution of a sophisticated clinical development plan with highly skilled medical specialists at top-tier radiopharmaceutical institutions. Through our clinical pipeline, Coretag aims to demonstrate the efficacy of its Tumor Necrosis Targeting Platform®. Our goal is to develop CyanCore Therapy® for treatment of various aggressive malignancies by establishing strategic partnerships major pharmaceutical companies in the US and Europe, including also Switzerland and the UK.
Private Placement
for raising $60 Million
To fund our Phase 1a (Theranostics Step 1: safety, dosimetry, necrosis diagnosis) and Phase 1b (preliminary efficacy) clinical trials in solid tumors, we shortly launch our first private placement program to raise $60 million through the issuance and placement of new shares with professional investors. If you are a professional investor and are interested in knowing more about investing in our company and contributing to the development of potentially groundbreaking treatment for cancer, please fill out the form to receive our Private Placement Memorandum.
Financial Statements
PDF
PDF
Governance
We apply all the main and supporting principles of good corporate governance following the USA Corporate Governance Code and related guidance.
After the first closing of USD 30 million, Coretag installs a Board of Directors which shall be collectively with the operational management team responsible for the success of Coretag, Inc. The Board maintains and periodically reviews a list of matters that can only be approved by the Board. Matters that have not been expressly reserved to the Board, will be delegated to the CEO or one of the pre-defined Board’s Committees. The diagram below illustrates this governance structure.
Board of Directors
To be installed in Q1 2025
Chief Executive Officer & Chief Medical Officer
Dr. Setareh Shamsili MD, PhD
Chief Financial Officer
Markwin H. Maring
The Board’s responsibilities include setting Coretag,inc strategy and policies, overseeing risk and corporate governance, and monitoring progress towards meeting our predefined company objectives and annual plans and is accountable to our shareholders.
The CEO/CMO and CFO take the lead in developing our strategy; proposals are reviewed and constructively challenged by the Board before the strategy is approved.
PDF
PDF
PDF
FAQ’s
Coretag has chosen a lean operational business model with sourcing and utilizing on demand research and development capacity with highly skilled and experienced professionals and top of the line medical hospitals in North America and Europe . The pipeline development is managed and controlled by a dedicated executive team within Coretag which consists of the following roles: CEO, CMO, CFO, and executive roles of clinical development, preclinical research, non-clinical R&D, regulatory, nuclear medicine medical director and legal expert. The key expertise head count in the near future, will be approximately 10 employees, and with moving towards more demanding stages, the head count will increase accordingly. In addition, we secure regular retainer contracts with other required functions such as IT support, Office managers, medical writers, clinical oncology statisticians and pharmacovigilance experts. We outsource the execution of clinical trials to applicable vendors, as well as outsourcing preclinical research to academic centers and commercial vendors, with close supervision by our in-house C-Suite and Executives. Further details about Coretag ,Inc. partnerships and teams will be presented in our annual report 2024.
Coretag, Inc. is an OTC company which shall enter the Nasdaq after the private placement of USD 60 million gets fulfilled. The symbol of Coretag, Inc. is COTI.
Coretag adheres to the International Financial Reporting Standards (IFRS) and International Accounting Standards (IAS) with appropriate conversion to US GAAP being shown in our financial statements.
Coretag reports in US dollars($).
Coretag, Inc. started by the reversed takeover of Coretag Therapeutics AG, a Switzerland registered company which owns the exclusive rights and license to develop a clinical pipeline (both diagnostic and therapeutic) for solid tumors and based on the patented Coretag Necrosis Targeting Platform Technology®. To fund its further development, Coretag Holding AG has decided to list the Coretag activities through a reversed takeover of a clean and unencumbered publicly trading OTC company. Coretag initiated a private placement to fund USD 60 million in total over the coming two years of which the first USD 30 million is expected to be raised before the end of Q1 2025.
Coretag, Inc. is a biotech development company which has the goal to gather medical data which proves the safety and efficacy of its theranostic compounds NS-SCAN® and CyanCore Therapy®. Based on clinical proof of concept and the supporting data, Coretag aims to partner with strategic partners with the goal of selling its pipeline and activities to big pharma. Based on this strategy, Coretag during its research and development phase, most probably shall not pay (interim)dividends to its shareholders. In the case of a (partly) acquisition of its pipeline development or subsidiary Coretag Therapeutics AG, it can be expected that a strategic buyer makes an offer on all outstanding trading shares.
A ‘Boiler Room’ fraud may take different forms but typically involves the use of high-pressure sales techniques and the promise of opportunities that appear too good to be true. Coretag, Inc. shareholders may be targeted by unsolicited phone calls or correspondence from ‘brokers’ who are often based overseas concerning investments and promising high financial returns. Unfortunately, the high profits promised never to materialize and shareholders are often left significantly out of pocket. The ‘brokers’ are often both persistent and extremely persuasive with even experienced investors falling victim to the scams. This type of fraud is called ‘boiler room’ fraud because of the high-pressure sales techniques used by the “brokers”.
Coretag, Inc. shareholders are advised to be extremely cautious of any unsolicited approaches offering advice, free reports and offers to buy shares at a discount or sell at an inflated price.
In the event that you receive unsolicited contact regarding an investment opportunity, FINRA and SEC offer the following advice, full details of which can be found on their websites:
• Reject any cold calls;
• Take the name of the person that has contacted you along with the full name and address of the organization which they purport to work for;
• The SEC and FINRA strongly advise that individuals should only deal with financial services firms that are properly authorized. Check that the firm is correctly authorized by visiting FINRA Broker Check or call FINRA at (800) 289-9999orvisit the SEC’s Investment Adviser Public Disclosure (IAPD) website. Also, contact your state securities regulator;
• Check whether the firm appears on the SEC warning list;
• Seek impartial advice from a financial adviser before you make an investment.
Explore more
Experience our unique approach
Discover how Coretag's innovative strategies are transforming cancer care and see how we're leading the way in targeted therapy and diagnostics.
Discover our scientific research journey
Delve into the current stages of our research, where innovative discoveries are shaping the future of cancer treatment.